1. M. Shi, B. Shen, C. Wang, et al. Double-dose Firmonertinib (AST2818; formerly furmonertinib) as First-line Treatment in Patients with EGFR exon 21 L858R Mutation-Positive Non-Small-Cell Lung Cancer: Results from FIRM study. 2024 ESMO ASIA. 658P 2. Harrison PT, Vyse S, Huang...
2.Lu Shun, Dong Xiaorong, Jian Hong, et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.[J] .J Clin Oncol, 2022, 40: 3162-3171....
目前EGFR-TKI单药治疗仍然存在诸多未被满足的临床需求,首先针对EGFR L858R突变,由于其突变位点多位于C-lobe活化环的A-loop区域,距ATP结合位点较远,与TKI结合的亲和力不够高,单药治疗效果不如19del突变理想[10],多项研究在L858R突变人群进...
4 Li X, Zhang L, Jiang D, et al. Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial[J]. Clinical Cancer Research, ...
目前EGFR-TKI单药治疗仍然存在诸多未被满足的临床需求,首先针对EGFR L858R突变,由于其突变位点多位于C-lobe活化环的A-loop区域,距ATP结合位点较远,与TKI结合的亲和力不够高,单药治疗效果不如19del突变理想[10],多项研究在L858R突变人群进行了探索,如一代TKI埃克替尼加量治疗(PFS 12.9个月)、二代TKI达克替尼...
[2] Li W Q, Cui J W. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments[J]. Journal of Cancer Research and Clinical Oncology, 2020, 146(9): 2329-2338. ...
exon 21 point mutation, L858R），携带此类突变的NSCLC患者对酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）高度敏感；其他确定的非典型突变EGFR S768I、L861Q和G719X对TKIs中度敏感，但表现出异质性和降低的反应；而20外显子的T790M突变和部分外显子20插入突变（exon 20 insertions, Ex20ins）对TKIs不...
EGFR外显子21的L858R突变(Exon 21 L858R point mutation) 这两种突变类型在EGFR突变阳性肺癌患者中占比较高,达克替尼对这些患者表现出显著的疗效。 2、选择达克替尼的关键依据 EGFR突变类型:达克替尼对特定的EGFR突变类型效果显著。 一线治疗或二线治疗:达克替尼作为第二代抑制剂,在一线治疗中表现出优于第一代抑制...
Methods: A total of 95 cases of lung adenocarcinoma patients with EGFR gene 21 exon L858R mutation treated in the Chongqing Cancer Hospital from January 2012 January 2016 were divided into the chemotherapy group(n=54) and target group(n=41) according to the ...
EGFR Exon20ins突变是一类EGFR突变的亚型，是继EGFR19外显子缺失（19-Del）和21外显子L858R点突变（21-L858R）两大常见突变外EGFR的第三大突变。其空间构象与野生型EGFR非常相似，还有着相似的结合模式和表观亲和力，这就导致其安全治疗窗很窄，让开发兼顾疗效和安全性的靶向药物难度骤升。EGFR各突变类型所占比例 ...